OSLER studies Compelling data on PCSK9 inhibition
News • 16-3-2015
Dr. Marc S Sabatine MD, Boston, Chairman of TIMI Study Group and Professor, Harvard Medical School, describes the very compelling results of OSLER 1 and 2 studies with evolocumab and the potential for PCSK9 inhibition to reduce major cardiovascular events through robust LDL-c reduction.
3 minute education • 16-3-2015, ACC 2015, San Diego, Prof.dr. John Kastelein